There's nothing to comment on really, given the limited amount of news the company releases. Best to just be patient and not focus on the stock on a day-to-day basis (might go crazy otherwise).
NEU Neuren Pharmaceuticals dips after pediatric Angelman Syndrome Phase 2 trial results fail to impress
